Sign In
Buy CAI
$17.31
-1.16 (-6.28%)
At Close: Jun 22, 2026
CAI Named to Newsweek's America's Greatest Workplaces in Tech 2026
09:06am, Wednesday, 17'th Jun 2026
ALLENTOWN, Pa., June 17, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, today announced it has been named to Newsweek's America's Greatest Workplaces in Tech 2026 list.
Caris Life Sciences Announces Dual Listing on NYSE Texas
08:30am, Tuesday, 16'th Jun 2026
IRVING, Texas, June 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced the dual
Caris Life Sciences: The Discount To Peers Looks Hard To Ignore
07:57am, Friday, 12'th Jun 2026
Caris Life Sciences is rated a buy, combining 79% Q1 2026 revenue growth, 65%+ gross margins, and positive free cash flow. CAI's genomic database of over one million cases underpins future products li
Caris Life Sciences, Inc. (CAI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
03:48pm, Monday, 08'th Jun 2026
Caris Life Sciences, Inc. (CAI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Caris Life Sciences Announces Share Repurchase Program
08:30am, Monday, 08'th Jun 2026
IRVING, Texas, June 8, 2026 /PRNewswire/ -- Caris Life Sciences® (Nasdaq: CAI) ("Caris" or the "Company"), a leading next-generation AI TechBio company and precision medicine pioneer, today announced
Capitan Investment Ltd. Announces Adoption of Semi-Annual Reporting
02:11pm, Thursday, 28'th May 2026
Calgary, Alberta--(Newsfile Corp. - May 28, 2026) - Capitan Investment Ltd. (TSXV: CAI) (the "Corporation") announces that it has elected to adopt semi-annual financial reporting in reliance on the Co
Inaugural story spotlights a woman whose presumed stage 4 metastatic breast cancer diagnosis was corrected by Caris GPSai, an AI-powered tissue-of-origin model, revealing a highly treatable lymphoma I
CAI Advances Multicloud and Secure AI Strategy with AWS and Microsoft
09:02am, Wednesday, 20'th May 2026
ALLENTOWN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, with more than 40 years of expertise delivering technology solutions to public sector and commercial organizations, announ
Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris
The Caris Lookback Program identified 13,293 patients potentially eligible for newly approved targeted therapies across 10 tumor types IRVING, Texas, May 15, 2026 /PRNewswire/ -- Caris Life Sciences®
Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%
05:06am, Wednesday, 13'th May 2026
Caris Life Sciences NASDAQ: CAI executives said the company is expanding its commercial reach, product pipeline and biopharma partnerships as it looks to build on recent revenue growth following its I
Caris Life Sciences, Inc. (CAI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
03:40pm, Tuesday, 12'th May 2026
Caris Life Sciences, Inc. (CAI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Targeted gene panels miscalculate tumor mutational burden in 10–15% of patients, directly resulting in incorrect pembrolizumab eligibility determination IRVING, Texas, May 11, 2026 /PRNewswire/ -- C
IRVING, Texas, May 8, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced that it has
Caris Life Sciences, Inc. (CAI) Q1 2026 Earnings Call Transcript
10:41am, Friday, 08'th May 2026
Caris Life Sciences, Inc. (CAI) Q1 2026 Earnings Call Transcript
